| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H12I2O4 |
| Molecular Weight | 510.0623 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1
InChI
InChIKey=WONYMNWUJVKVII-UHFFFAOYSA-N
InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)
| Molecular Formula | C15H12I2O4 |
| Molecular Weight | 510.0623 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
3,5-Diiodothyropropionic acid (DITPA), a carboxylic acid analog with low metabolic activity, was observed to induce alpha-MHC mRNA in heart cell culture with EC50 approximately 5 x 10(-7) M. Zarion Pharmaceuticals was developing DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analogue, for the treatment of Allan-Herndon-Dudley syndrome. In May 2013, the US FDA granted DITPA orphan drug status for the treatment of Allan-Herndon-Dudley syndrome. However, development of DITPA for the treatment of Allan-Herndon-Dudley syndrome was discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
PubMed
Sample Use Guides
Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients:
Sixty (60) patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 20 patients per treatment group):
DITPA at 90 mg/day (45 mg twice a day [BID] taken orally)
DITPA at 180 mg/day (90 mg BID taken orally)
Those patients randomized to receive DITPA at 90 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for 10 weeks.
Those patients randomized to receive DITPA at 180 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for the next 2 weeks, and then 180 mg/day for 8 weeks.
Route of Administration:
Oral
